key: cord-0986686-x81i5365 authors: Yue, H.; Nowak, R. P.; Overwijn, D.; Payne, N. C.; Fischinger, S.; Atyeo, C.; Baden, L. R.; Nilles, E. J.; Karlson, E. W.; Yu, X. G.; Li, J. Z.; Alter, G.; Mazitschek, R.; Fischer, E. S. title: Rapid 'mix and read' assay for scalable detection of SARS-CoV-2 antibodies in patient plasma date: 2020-09-03 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2020.09.01.20184101 sha: 5f46563960a6571320f4654f8638794d52e364b6 doc_id: 986686 cord_uid: x81i5365 The human beta coronavirus SARS-CoV-2, causative virus of COVID-19, has infected more than 15 million people globally and continues to spread. Widespread, population level testing to detect active and past infections is critical to curb the COVID-19 pandemic. Antibody (serological) testing is the only option for detecting past infections outside the narrow window accessible to nucleic acid-based tests. However, currently available serological assays commonly lack scalability. Here, we describe the development of a rapid homogenous serological assay for the detection of antibodies to SARS-CoV-2 in patient plasma. We show that the fluorescence-based assay accurately detects seroconversion in COVID-19 patients from less than 1 microliter of plasma. Using a cohort of samples from COVID-19 infected or healthy individuals, we demonstrate detection with 100% sensitivity and specificity. This assay addresses an important need for a robust, low barrier to implementation, and scalable serological assay with complementary strengths to currently available serological platforms. SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) is a human beta-coronavirus that has caused a global pandemic of coronavirus disease 2019 (COVID-19) 1 . To better understand the spread of the disease and manage public health responses, rapid and ideally population wide screening is essential. Nucleic acid-based tests for the identification of infected individuals have been widely implemented 2 , but these tests can only detect the virus during a narrow window of acute disease. Robust serological assays are necessary to identify individuals who have previously been infected and developed antibodies to SARS-CoV-2. Such serological assays for SARS-CoV-2 antibodies are also critical to identify individuals with asymptomatic disease 3, 4 . Serological testing can establish the spread of the virus within a population and help epidemiologists to accurately model the prevalence of COVID-19. Important to the large number of efforts to develop SARS-CoV-2 vaccines, robust serological testing assays provide means to monitor level and duration of response in clinical trials as well as trace serological response in the general population post-vaccination. The serological assays currently used to detect anti-SARS-CoV-2 antibodies are either enzymelinked immunosorbent assays (ELISA) or commercial solutions on large diagnostics platforms 3, 5-12 . However, these strategies have several critical limitations [13] [14] [15] [16] [17] . ELISA assays suffer from limited scalability, mainly due to multi-step protocols with extensive wash steps that lead to the need for specialized equipment and automation. Other available assays are not quantitative and require specialized analytical laboratory platforms that are not widely available. To address these limitations, we developed a robust, "mix and read" assay for the detection of SARS-CoV-2 antibodies based on time-resolved Förster resonance energy transfer (TR-FRET). Given its homogenous nature, the assay is highly scalable and does not require complex automation. In direct comparison with the current state-of-the-art ELISA or commercial assays, our TR-FRET assay platform performs with comparable or superior specificity and sensitivity, while the processing time is reduced to ~ 1 hour compared to several hours for ELISA. Importantly, the lack of multiple steps, including extensive washes, results in superior repeatability and reproducibility and makes the assay suitable for manual operation as well as highly scalable automation. We report the development and validation of a homogenous serological assay platform for the detection of SARS-CoV-2 antibodies in human plasma/serum (Fig. 1a) . The direct detection of a ternary complex between antigen and serum antibodies using a TR-FRET readout allows for a simple mix and read protocol that lends itself to scalable automation (Fig. 1b) . The proximity of the donor (Terbium) and acceptor (BODIPY) fluorophores induced by presence of serum antibodies results in a positive TR-FRET signal that is read out as a 520 nm (acceptor) / 490 nm (donor) ratio and allows for accurate quantification of serum antibodies in an isotype specific manner (Fig. 1a) . To enable sensitive detection, we optimized assay conditions to minimize the signal-to-noise ratio as follows. We first established that the TR-FRET assay format can detect the binding of immunoglobulin variants IgG, IgM and IgA1 to SARS-CoV-2 antigens (Fig. 1c) . The SARS-CoV-2 spike protein (S protein) is responsible for binding to the host receptor ACE2 to mediate virus entry upon infection 18 and most neutralizing antibodies have been found to target the S protein 19 . Terbium or BODIPY. As positive control, we used recombinantly expressed SARS-1 IgG antibody CR3022 20 that has been shown to cross-react with the RBD of SARS-CoV-2 (Kd of 9.1 ± 0.7 nM, Fig. S1a ) and IgM and IgA1 antibodies engineered to contain the CR3022 variable region 21 . To identify ideal labeling positions, titrations of CR3022 (IgG, IgM, IgA1) into a mix of labeled S-RBD and labeled detection antibody were performed while varying the position of donor and acceptor (either on S-RBD or detection antibody) (Fig. S1b, c) . While we found that all combinations lead to a functional readout (Fig. S1d, e) , we observed that terbium conjugation to the antigen results in optimal performance when used with serum/plasma samples. We therefore selected labeling the antigen with terbium and the detection antibody with BODIPY, resulting in quantitative binding curves for CR3022 (IgG/IgM/IgA1) (Fig. 1c) . The binding curves exhibit the characteristic bell-shape due to the prozone effect 22 , which can be accurately accounted for by mathematical models 23 . Next, we established that CR3022 can similarly be detected in human serum (Fig. 1d) , and while the signal is reduced, the low background level allows for accurate quantification. During the optimization of assay conditions, we noticed that replacing RBD with the full-length SARS-CoV-2 spike protein (S protein) significantly reduced background particularly in the presence of serum. This is likely due to 1) the trimeric nature of the full-length S protein leading to avidity effects; and 2) the exposure of otherwise shielded RBD surfaces that may cause unspecific interactions. We therefore continued all further validation using S protein and subsequently optimized the concentrations of antigen and detection antibody (Fig. S2a, b) . With optimized concentrations, we validated that convalescent serum results in a dose dependent response in TR-FRET signal (Fig. 1e) . To test the detection of antibodies in serum obtained from positive and negative controls, a set of 49 PCR tested positive (CoV2+) patients from Mass General and Brigham and Women's Hospital, 28 PCR tested negative (healthy, CoV2-) patients from Mass General Hospital, as well as 19 pre-pandemic serum samples from Mass General Brigham Biobank (CoV2-) or community volunteers (CoV2-) was assembled (hereafter referred to as 96w_testset). Adapting established protocols 24 , we performed an ELISA assay using S protein as reference (Fig. 2a) . We next profiled the 96w_testset with our TR-FRET assay at an initial serum dilution of 1:100 to match the exact ELISA concentration (Fig. 2b) , and found that using a 3 standard deviations (SD) cutoff away from the healthy control mean, the TR-FRET achieves 94.9% sensitivity and 100% specificity while the ELISA achieves 100% sensitivity and 96.6% specificity. We observe a strong correlation between the TR-FRET and ELISA assays (Fig. 2c) . While the discrimination between CoV2+ and CoV2-was comparable between TR-FRET and ELISA, we found that the ELISA had stronger signal compared to TR-FRET especially for low responders. This can be explained by the signal amplification in the ELISA compared to equilibrium binding of the TR-FRET assay. However, the lower signal is offset by the low background noise of the TR-FRET. We nevertheless wondered whether signal could further be boosted without compromising background noise by increasing the serum concentration, and how the assay would react to changes in serum dilution. We re-assayed the 96w_testset using dilution factors of 1:150 or 1:50 and observed that increasing the serum concentration improves signal strength without compromising background noise (Fig. 2d, e) . Lowering the serum concentration to 1:150 only marginally reduces performance (Fig. 2f, g) . When analyzing this initial 96w_testset, we observed several CoV2+ samples with unexpected low response. We hypothesized that this might be the result of epitope masking since the TR-FRET assay utilizes covalent labeling of the antigen with terbium. We therefore sought to ensure minimal epitope masking and optimized the Degree of Labelling (DOL) (Fig. S3) . We found that a DOL ~ 3.8 resulted in no detectable epitope masking with optimal signal and therefore a DOL ~ 3.8 was ensured for all further experiments. With optimized conditions and DOL, we next used the TR-FRET assay to detect seroconversion in a larger set of samples from the Mass General Brigham Biobank containing 68 SARS-CoV-2 PCR positive samples (CoV2+), and 100 pre-pandemic healthy controls (CoV2-) (hereafter referred to as MGB set) that was again profiled using the established ELISA assay for reference and has also been profiled with different commercial and academic assays 25 . In line with our previous observations, the standard deviation of the healthy controls was very low, and accurate discrimination between CoV2+ and healthy samples was achieved with 100% specificity and 100% sensitivity using a cut-off based on 3 SD of the healthy control (Fig. 3a) . The results are comparable to the established ELISA assay on the same sample set (Fig. 3b) , and the response of individual samples between TR-FRET and ELISA assays was well correlated (Pearson correlation coefficient of 0.91) (Fig. 3c) . In order to assess the limit of detection (LoD) of the TR-FRET assay, we first performed a titration of control antibody CR3022 IgG in the presence and absence of negative control serum at 1:150 serum to buffer dilution (Fig. 4a) . The prozone effect is clearly visible at higher concentrations of the antibody and signal intensity is reduced in the presence of serum. We next selected the lowest concentrations of CR3022 IgG antibody where signal was higher than mean + 3 SD and compared 20 replicates against the 20 replicates of blank control both in presence and absence of serum (Fig, 4b) . Based on this, the LoD for the TR-FRET assay was determined to be 1.22 ng/mL in absence of serum, and 39 ng/mL in presence of the serum, which is in the range of common ELISA LoD 26 . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 3, 2020. . https://doi.org/10.1101/2020.09.01.20184101 doi: medRxiv preprint Eliminating the wash steps and reducing the overall number of sample handling steps should result in high reproducibility and repeatability. To assess the intra-and inter-assay precision of the TR-FRET assay we selected a set of positive responders as well as negative control samples (68 total) and performed the assay with three operators on three different days (Fig. 4c, d) . The correlation between operators was above 99.6% with average repeatability of 4.31% and overall precision across days and operators of 5.72%, which well exceeds the commonly desired range for serological assays. Having established a serological assay for S protein, we set out to assess whether the TR-FRET setup is compatible with other antigens. S protein is one of the most widely studied antigens in serological assays for SARS-CoV-2, but there are other SARS-CoV-2 proteins that are highly immunogenic 27 , such as the abundant nucleocapsid protein (N protein) that binds to viral RNA inside the virion 28, 29 . We established an N protein TR-FRET IgG detection assay (thereafter named N TR-FRET). We used the same TR-FRET setup, with the donor fluorophore on the antigen and the acceptor fluorophore on the aIgG antibody. The commercially obtained N protein was biotinylated and terbium-streptavidin conjugate was used to label the antigen. To validate the assay setup, we performed a titration of convalescent CoV2+ serum into biotinylated N protein, Tb-Streptavidin and BODIPY-aIgG. We observed a dose response with strong signal present at lower dilution (1:50), consistent with our S-protein TR-FRET (Fig. S4) . We next performed N TR-FRET on the 96w_testset which resulted in a sensitivity of 97.6% and specificity 96.6% (Fig. 5a) . Comparing the S and N TR-FRET readouts on the 96w_testset All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 3, 2020. . https://doi.org/10.1101/2020.09.01.20184101 doi: medRxiv preprint resulted in a Pearson Correlation coefficient of 0.47, indicating that the two assays are orthogonal and likely provide additive information on serological status when combined (Fig. 5b ). We describe the development of a homogenous serological assay based on TR-FRET detection, which as we demonstrate provides a scalable alternative to current assay platforms. While assays with signal amplification such as ELISA 30 , or digitized detection such as SIMOA 31 , in theory offer superior detection of low levels of analyte, the TR-FRET assay described here offsets this by low background, allowing for sensitive, accurate detection of SARS-CoV-2 seroconversion. The lack of signal amplification biases the assay towards superior specificity due to very stable background signal, and results in robust reproducibility and repeatability (CV < 5%). When compared to common commercial or ELISA assays on the same samples, the homogenous TR-FRET assay performs equivalent or superior in discriminating SARS-CoV-2 25 . As we demonstrate with the use of biotinylated N protein, the TR-FRET assay setup offers a flexible platform for rapid onboarding of new antigens of the same pathogen, and can also be easily adapted for testing other pathogens or analytes. The flexibility of 'in solution' detection will further allow for future applications such as isotype specific detection, multiple antigens in a single "mix and read" reaction, or the detection of specific epitopes. In conclusion, the TR-FRET assay fulfills an unmet need for a serological assay that is scalable and has a very low implementation barrier. The scalability arises from the lack of washing steps or sequential manipulations, which lends itself to simple automation using widely available robotic platforms to achieve hundred thousand tests a day. The simplicity of the assay format also makes it easy to implement, as for reproducible results no automated plate washers or similar liquid handling systems are required. With widely available plate readers, one operator All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 3, 2020. . https://doi.org/10.1101/2020.09.01.20184101 doi: medRxiv preprint could perform several hundred tests a day using manual multichannel pipettes without sacrificing accuracy of the results. Lastly, the miniaturization and lack of large volume wash steps leads to very low costs of the assay. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 3, 2020. . https://doi.org/10.1101/2020.09.01.20184101 doi: medRxiv preprint The full-length Spike protein of SARS-CoV-2 (S protein prefusion stabilized with furin site removed, expressed in TunaCHO) was purchased from LakePharma (Cat. 46328), RBD of SARS-CoV-2 was purchased from LakePharma (Cat. 46438) and full-length biotinylated N protein of SARS-CoV-2 (construct 1-419 with N terminal His-Avi tag) was purchased from Acro biosystem (Cat. NUN-C81Q6). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 3, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 3, 2020. . https://doi.org/10.1101/2020.09.01.20184101 doi: medRxiv preprint using 0.5 ml elution fractions. Protein containing fractions were pooled and flash-frozen in liquid nitrogen at 0.4-0.6 mg/ml concentration and stored at -80°C. The corrected A280 value (A280,corr) of protein conjugate was determined via Nanodrop (0.1 cm path length) by measuring A280 and A340, using equation 1: where cf is the correction factor for the Tb complex contribution to A280 and is equal to 0.157. The concentration of protein conjugate, cab (M) was determined using equation 2: where ε is the antibody extinction coefficient at A280, equal to 210,000 M -1 cm -1 for IgG class anti All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 3, 2020. recorded with a 70 μs delay over 130 μs to reduce background fluorescence and the reaction was followed over >20 or >100 second cycles of each data point using a PHERAstar FS All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 3, 2020. . https://doi.org/10.1101/2020.09.01.20184101 doi: medRxiv preprint microplate reader (BMG Labtech). The TR-FRET signal of each data point was extracted by calculating the 520/490 nm ratio. Dilution of tested human serum samples were added to assay mix with final concentrations of (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 3, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 3, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Fig. 1c and Fig. 1d are represented as means ± SD of two replicates (n = 2). e, titration of positive and negative serum in final assay condition 250 nM BODIPY-aIgG and 7.5 nM Tb-S. Data in Fig. S2 are represented as means ± SD of three replicates (n = 3). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 3, 2020. . https://doi.org/10.1101/2020.09.01.20184101 doi: medRxiv preprint precision (calculated across days and operators) corresponding to data in Fig. 4a . Data are represented as means ± SD of two replicates (n = 2). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 3, 2020. . https://doi.org/10.1101/2020.09.01.20184101 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 3, 2020. . https://doi.org/10.1101/2020.09.01.20184101 doi: medRxiv preprint A Novel Coronavirus Emerging in China -Key Questions for Impact Assessment Laboratory Diagnosis of COVID-19: Current Issues and Challenges Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections Opportunity of periodic monitoring of COVID-19 patients, asymptomatic virus carriers, and postinfectious individuals with IgM/IgG rapid antibody tests among healthcare workers during SARS-CoV-2 pandemic A serological assay to detect SARS-CoV-2 seroconversion in humans The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients Rapid roll out of SARS-CoV-2 antibody testing: even at high levels of specificity, an important proportion of test results will be false positives Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics? SARS-CoV-2 antibody testing-questions to be asked The Role of Antibody Testing for SARS-CoV-2: Is There One? Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients Recent developments in emerging microimmunoassays Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak Antibody responses against SARS-CoV-2 in COVID-19 patients Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody The Prozone Effect Accounts for the Paradoxical Function of the Cdk-Binding Protein Suc1/Cks A comprehensive mathematical model for three-body binding equilibria SARS-CoV-2-specific ELISA development Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2. medRxiv High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Nucleocapsid-independent specific viral RNA packaging via viral envelope protein and viral RNA signal Enzyme-linked immunosorbent assay (ELISA) Single-Molecule Arrays for Protein and Nucleic Acid Analysis We would like to thank Dr. Xu Yu and the Massachusetts Coalition for Pandemic Readiness for additional samples provided by the Ragon Institute. This work was supported by a philanthropic gift from Giving | Grousbeck Fazzalari (to E.S.